Evolution strategy of ROS1 kinase inhibitors for use in cancer therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Future medicinal chemistry"
DOI: 10.4155/fmc-2018-0033
Abstract: The abnormal expression of c-ros oncogene1 receptor tyrosine kinase (ROS1) has been identified as clinically actionable oncogenic driver in non-small-cell lung cancer. Since crizotinib was approved by the US FDA for the treatment of advanced… read more here.
Keywords: strategy ros1; kinase; evolution strategy; ros1 kinase ... See more keywords